Harmony Biosciences Holdings, Inc.
HRMY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $715 | $582 | $438 | $305 |
| % Growth | 22.8% | 32.9% | 43.4% | – |
| Cost of Goods Sold | $157 | $121 | $83 | $56 |
| Gross Profit | $558 | $461 | $354 | $250 |
| % Margin | 78.1% | 79.2% | 80.9% | 81.8% |
| R&D Expenses | $146 | $76 | $71 | $30 |
| G&A Expenses | $110 | $95 | $84 | $64 |
| SG&A Expenses | $221 | $193 | $163 | $132 |
| Sales & Mktg Exp. | $111 | $97 | $79 | $68 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $367 | $269 | $234 | $162 |
| Operating Income | $191 | $192 | $120 | $88 |
| % Margin | 26.7% | 33% | 27.4% | 28.7% |
| Other Income/Exp. Net | $1 | -$19 | -$16 | -$50 |
| Pre-Tax Income | $192 | $173 | $105 | $37 |
| Tax Expense | $46 | $45 | -$77 | $3 |
| Net Income | $145 | $129 | $181 | $35 |
| % Margin | 20.4% | 22.1% | 41.4% | 11.3% |
| EPS | 2.56 | 2.17 | 3.07 | 0.6 |
| % Growth | 18% | -29.3% | 411.7% | – |
| EPS Diluted | 2.51 | 2.13 | 2.97 | 0.58 |
| Weighted Avg Shares Out | 57 | 59 | 59 | 58 |
| Weighted Avg Shares Out Dil | 58 | 60 | 61 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19 | $15 | $3 | $0 |
| Interest Expense | $17 | $24 | $19 | $24 |
| Depreciation & Amortization | $24 | $24 | $23 | $19 |
| EBITDA | $233 | $222 | $147 | $80 |
| % Margin | 32.7% | 38.1% | 33.5% | 26.3% |